S4C3:Biosimilars

原文始发于微信公众号(化学音乐文化):S4C3:Biosimilars

S4C3:Biosimilars

JanFourman,PhD, EdD,MBA, MSRA

S4C3:Biosimilars

Eli Lilly – Pharma registration for diabetes/endocrine, women/men’s health, neural science, oncology, bone/muscle/joint therapeutic areas – 5 years
Eli Lilly – Pharmacovigilance – 7 years
Eli Lilly – Regulatory Intelligence – 3 Years
Purdue University and Roche Diagnostics – Teaching global pharma development, Africa and US
Consultant for Indiana Technical Assistance Program
Invited conference speaker
Published author

S4C3:Biosimilars
S4C3:Biosimilars

扫描左侧二维码,获取视频课;扫描右侧二维码,获取音频课

Biosimilars

Introduction

Clinical Development

NDA Application and Approval

Commercialization

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部
S4C3:Biosimilars | 药时代

S4C3:Biosimilars

原文始发于微信公众号(化学音乐文化):S4C3:Biosimilars

S4C3:Biosimilars

JanFourman,PhD, EdD,MBA, MSRA

S4C3:Biosimilars

Eli Lilly – Pharma registration for diabetes/endocrine, women/men’s health, neural science, oncology, bone/muscle/joint therapeutic areas – 5 years
Eli Lilly – Pharmacovigilance – 7 years
Eli Lilly – Regulatory Intelligence – 3 Years
Purdue University and Roche Diagnostics – Teaching global pharma development, Africa and US
Consultant for Indiana Technical Assistance Program
Invited conference speaker
Published author

S4C3:Biosimilars
S4C3:Biosimilars

扫描左侧二维码,获取视频课;扫描右侧二维码,获取音频课

Biosimilars

Introduction

Clinical Development

NDA Application and Approval

Commercialization

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部